{"url_path":"/sec/bctx/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-06-09","source_url":"https://www.sec.gov/Archives/edgar/data/1610820/0001493152-26-027928-index.html","accession_number":"0001493152-26-027928","cik":"0001610820","ticker":"BCTX","issuer_name":"BriaCell Therapeutics Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1610820/0001493152-26-027928-index.html","primary_entity_key":"0001610820","primary_entity_name":"BriaCell Therapeutics Corp."},"word_count":1476,"has_tables":true,"body_markdown":"false\nQ3\n--07-31\n0001610820\n\nUnlimited\nUnlimited\n\nUnlimited\n\n0001610820\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:CommonSharesNoParValueMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:WarrantsToPurchaseCommonSharesNoParValueMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:WarrantsToPurchaseCommonSharesNoParValueOneMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:WarrantsToPurchaseCommonSharesNoParValueTwoMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\n2026-06-09\n\n0001610820\n\n2026-04-30\n\n0001610820\n\n2025-07-31\n\n0001610820\n\n2024-08-01\n2025-07-31\n\n0001610820\n\n2026-02-01\n2026-04-30\n\n0001610820\n\n2025-02-01\n2025-04-30\n\n0001610820\n\n2024-08-01\n2025-04-30\n\n0001610820\n\nus-gaap:CommonStockMember\n\n2026-01-31\n\n0001610820\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-31\n\n0001610820\n\nus-gaap:WarrantMember\n\n2026-01-31\n\n0001610820\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2026-01-31\n\n0001610820\n\nus-gaap:RetainedEarningsMember\n\n2026-01-31\n\n0001610820\n\nus-gaap:NoncontrollingInterestMember\n\n2026-01-31\n\n0001610820\n\n2026-01-31\n\n0001610820\n\nus-gaap:CommonStockMember\n\n2025-07-31\n\n0001610820\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-07-31\n\n0001610820\n\nus-gaap:WarrantMember\n\n2025-07-31\n\n0001610820\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-07-31\n\n0001610820\n\nus-gaap:RetainedEarningsMember\n\n2025-07-31\n\n0001610820\n\nus-gaap:NoncontrollingInterestMember\n\n2025-07-31\n\n0001610820\n\nus-gaap:CommonStockMember\n\n2025-01-31\n\n0001610820\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-31\n\n0001610820\n\nus-gaap:WarrantMember\n\n2025-01-31\n\n0001610820\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-01-31\n\n0001610820\n\nus-gaap:RetainedEarningsMember\n\n2025-01-31\n\n0001610820\n\nus-gaap:NoncontrollingInterestMember\n\n2025-01-31\n\n0001610820\n\n2025-01-31\n\n0001610820\n\nus-gaap:CommonStockMember\n\n2024-07-31\n\n0001610820\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-07-31\n\n0001610820\n\nus-gaap:WarrantMember\n\n2024-07-31\n\n0001610820\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2024-07-31\n\n0001610820\n\nus-gaap:RetainedEarningsMember\n\n2024-07-31\n\n0001610820\n\nus-gaap:NoncontrollingInterestMember\n\n2024-07-31\n\n0001610820\n\n2024-07-31\n\n0001610820\n\nus-gaap:CommonStockMember\n\n2026-02-01\n2026-04-30\n\n0001610820\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-02-01\n2026-04-30\n\n0001610820\n\nus-gaap:WarrantMember\n\n2026-02-01\n2026-04-30\n\n0001610820\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2026-02-01\n2026-04-30\n\n0001610820\n\nus-gaap:RetainedEarningsMember\n\n2026-02-01\n2026-04-30\n\n0001610820\n\nus-gaap:NoncontrollingInterestMember\n\n2026-02-01\n2026-04-30\n\n0001610820\n\nus-gaap:CommonStockMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nus-gaap:WarrantMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nus-gaap:RetainedEarningsMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nus-gaap:NoncontrollingInterestMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nus-gaap:CommonStockMember\n\n2025-02-01\n2025-04-30\n\n0001610820\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-02-01\n2025-04-30\n\n0001610820\n\nus-gaap:WarrantMember\n\n2025-02-01\n2025-04-30\n\n0001610820\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-02-01\n2025-04-30\n\n0001610820\n\nus-gaap:RetainedEarningsMember\n\n2025-02-01\n2025-04-30\n\n0001610820\n\nus-gaap:NoncontrollingInterestMember\n\n2025-02-01\n2025-04-30\n\n0001610820\n\nus-gaap:CommonStockMember\n\n2024-08-01\n2025-04-30\n\n0001610820\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-08-01\n2025-04-30\n\n0001610820\n\nus-gaap:WarrantMember\n\n2024-08-01\n2025-04-30\n\n0001610820\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2024-08-01\n2025-04-30\n\n0001610820\n\nus-gaap:RetainedEarningsMember\n\n2024-08-01\n2025-04-30\n\n0001610820\n\nus-gaap:NoncontrollingInterestMember\n\n2024-08-01\n2025-04-30\n\n0001610820\n\nus-gaap:CommonStockMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:WarrantMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:RetainedEarningsMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:NoncontrollingInterestMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:CommonStockMember\n\n2025-04-30\n\n0001610820\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-04-30\n\n0001610820\n\nus-gaap:WarrantMember\n\n2025-04-30\n\n0001610820\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-04-30\n\n0001610820\n\nus-gaap:RetainedEarningsMember\n\n2025-04-30\n\n0001610820\n\nus-gaap:NoncontrollingInterestMember\n\n2025-04-30\n\n0001610820\n\n2025-04-30\n\n0001610820\n\n2026-01-01\n2026-01-31\n\n0001610820\n\nBCTX:BriaProTherapeuticsCorpMember\n\n2026-02-18\n2026-02-18\n\n0001610820\n\nBCTX:BriaCellTherapeuticsMember\n\n2026-02-18\n2026-02-18\n\n0001610820\n\nus-gaap:CommonStockMember\n\n2026-02-18\n2026-02-18\n\n0001610820\n\nBCTX:BriaProTherapeuticsCorpMember\n\n2026-02-18\n\n0001610820\n\nBCTX:BCTherapeuticsMember\n\n2026-04-30\n\n0001610820\n\nBCTX:SharePurchaseAgreementMember\nBCTX:BCTherapeuticsMember\n\n2021-12-21\n2021-12-21\n\n0001610820\n\nBCTX:SharePurchaseAgreementMember\nBCTX:BCTherapeuticsMember\n\n2021-12-21\n\n0001610820\n\nBCTX:SharePurchaseAgreementMember\nBCTX:BCTherapeuticsMember\n\n2021-12-21\n\n0001610820\n\nBCTX:SharePurchaseAgreementMember\nBCTX:BCTherapeuticsMember\nBCTX:TwoOptionsMember\n\n2021-12-21\n2021-12-21\n\n0001610820\n\nBCTX:SharePurchaseAgreementMember\nBCTX:BCTherapeuticsMember\nBCTX:TwoOptionsMember\n\n2021-12-21\n\n0001610820\n\nBCTX:SharePurchaseAgreementMember\nBCTX:BCTherapeuticsMember\nsrt:MinimumMember\n\n2021-12-21\n2021-12-21\n\n0001610820\n\nBCTX:SharePurchaseAgreementMember\nBCTX:BCTherapeuticsMember\nsrt:MaximumMember\n\n2021-12-21\n2021-12-21\n\n0001610820\n\nBCTX:SharePurchaseAgreementMember\nBCTX:BCTherapeuticsMember\nBCTX:JuneTwoThousandTwentySevenMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:SharePurchaseAgreementMember\nBCTX:BCTherapeuticsMember\nBCTX:JuneTwoThousandTwentySevenMember\n\n2026-04-30\n\n0001610820\n\nBCTX:SharePurchaseAgreementMember\nBCTX:BCTherapeuticsMember\n\n2026-04-30\n\n0001610820\n\nBCTX:SharePurchaseAgreementMember\nBCTX:BCTherapeuticsMember\n\n2026-04-30\n2026-04-30\n\n0001610820\n\nBCTX:BCTherapeuticsMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:BCTherapeuticsMember\n\n2026-04-30\n\n0001610820\n\nBCTX:BCTherapeuticsMember\n\n2024-07-31\n\n0001610820\n\nBCTX:BCTherapeuticsMember\n\n2024-08-01\n2025-07-31\n\n0001610820\n\nBCTX:BCTherapeuticsMember\n\n2025-07-31\n\n0001610820\n\nBCTX:BCTherapeuticsMember\n\n2025-07-31\n\n0001610820\n\nsrt:MaximumMember\nBCTX:AmalgamationAgreementMember\n\n2026-04-30\n\n0001610820\n\nBCTX:AmalgamationAgreementMember\n\n2026-04-30\n\n0001610820\n\nBCTX:AmalgamationAgreementMember\nBCTX:BriaCellTherapeuticsMember\n\n2026-04-30\n\n0001610820\n\nBCTX:AmalgamationAgreementMember\nBCTX:BriaProTherapeuticsCorpMember\n\n2026-04-30\n\n0001610820\n\nBCTX:OfficeAndLabSpaceMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nus-gaap:FairValueInputsLevel1Member\nus-gaap:CashAndCashEquivalentsMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:FairValueInputsLevel2Member\nus-gaap:CashAndCashEquivalentsMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:CashAndCashEquivalentsMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:FairValueInputsLevel1Member\nus-gaap:CashAndCashEquivalentsMember\n\n2025-07-31\n\n0001610820\n\nus-gaap:FairValueInputsLevel2Member\nus-gaap:CashAndCashEquivalentsMember\n\n2025-07-31\n\n0001610820\n\nus-gaap:CashAndCashEquivalentsMember\n\n2025-07-31\n\n0001610820\n\nus-gaap:FairValueInputsLevel1Member\nus-gaap:ShortTermInvestmentsMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:FairValueInputsLevel2Member\nus-gaap:ShortTermInvestmentsMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:ShortTermInvestmentsMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:FairValueInputsLevel1Member\nus-gaap:ShortTermInvestmentsMember\n\n2025-07-31\n\n0001610820\n\nus-gaap:FairValueInputsLevel2Member\nus-gaap:ShortTermInvestmentsMember\n\n2025-07-31\n\n0001610820\n\nus-gaap:ShortTermInvestmentsMember\n\n2025-07-31\n\n0001610820\n\nus-gaap:FairValueInputsLevel1Member\n\n2026-04-30\n\n0001610820\n\nus-gaap:FairValueInputsLevel2Member\n\n2026-04-30\n\n0001610820\n\nus-gaap:FairValueInputsLevel1Member\n\n2025-07-31\n\n0001610820\n\nus-gaap:FairValueInputsLevel2Member\n\n2025-07-31\n\n0001610820\n\nus-gaap:FairValueInputsLevel1Member\nBCTX:WarrantsLiabilityMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:FairValueInputsLevel2Member\nBCTX:WarrantsLiabilityMember\n\n2026-04-30\n\n0001610820\n\nBCTX:WarrantsLiabilityMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:FairValueInputsLevel1Member\nBCTX:WarrantsLiabilityMember\n\n2025-07-31\n\n0001610820\n\nus-gaap:FairValueInputsLevel2Member\nBCTX:WarrantsLiabilityMember\n\n2025-07-31\n\n0001610820\n\nBCTX:WarrantsLiabilityMember\n\n2025-07-31\n\n0001610820\n\nus-gaap:FairValueInputsLevel1Member\nsrt:MinimumMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:FairValueInputsLevel1Member\nsrt:MaximumMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:FairValueInputsLevel1Member\nsrt:MinimumMember\n\n2025-07-31\n\n0001610820\n\nus-gaap:FairValueInputsLevel1Member\nsrt:MaximumMember\n\n2025-07-31\n\n0001610820\n\n2025-01-03\n2025-01-03\n\n0001610820\n\n2025-08-25\n2025-08-25\n\n0001610820\n\nBCTX:JanuaryTwoThousandTwentySixOfferingMember\n\n2026-01-15\n2026-01-15\n\n0001610820\n\nus-gaap:WarrantMember\n\n2026-01-15\n\n0001610820\n\nBCTX:PrefundedWarrantMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:PrefundedWarrantMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:WarrantMember\n\n2026-01-15\n2026-01-15\n\n0001610820\n\nBCTX:PlacementAgentWarrantsMember\n\n2026-01-15\n\n0001610820\n\nBCTX:PlacementAgentWarrantsMember\n\n2026-01-15\n\n0001610820\n\nBCTX:PrefundedWarrantMember\n\n2026-01-15\n2026-01-21\n\n0001610820\n\nus-gaap:CommonStockMember\n\n2026-01-15\n2026-01-21\n\n0001610820\n\nus-gaap:WarrantMember\nus-gaap:MeasurementInputSharePriceMember\n\n2026-01-15\n\n0001610820\n\nus-gaap:WarrantMember\nus-gaap:MeasurementInputExercisePriceMember\n\n2026-01-15\n\n0001610820\n\nus-gaap:WarrantMember\nus-gaap:MeasurementInputExpectedTermMember\n\n2026-01-15\n\n0001610820\n\nus-gaap:WarrantMember\nBCTX:MeasurementInputAnnualizedVolatilityMember\n\n2026-01-15\n\n0001610820\n\nus-gaap:WarrantMember\nus-gaap:MeasurementInputExpectedDividendRateMember\n\n2026-01-15\n\n0001610820\n\nus-gaap:WarrantMember\nus-gaap:MeasurementInputRiskFreeInterestRateMember\n\n2026-01-15\n\n0001610820\n\nBCTX:PlacementAgentWarrantsMember\n\n2026-01-15\n2026-01-15\n\n0001610820\n\nBCTX:PlacementAgentWarrantsMember\nus-gaap:MeasurementInputSharePriceMember\n\n2026-01-15\n\n0001610820\n\nBCTX:PlacementAgentWarrantsMember\nus-gaap:MeasurementInputExercisePriceMember\n\n2026-01-15\n\n0001610820\n\nBCTX:PlacementAgentWarrantsMember\nus-gaap:MeasurementInputExpectedTermMember\n\n2026-01-15\n\n0001610820\n\nBCTX:PlacementAgentWarrantsMember\nBCTX:MeasurementInputAnnualizedVolatilityMember\n\n2026-01-15\n\n0001610820\n\nBCTX:PlacementAgentWarrantsMember\nus-gaap:MeasurementInputExpectedDividendRateMember\n\n2026-01-15\n\n0001610820\n\nBCTX:PlacementAgentWarrantsMember\nus-gaap:MeasurementInputRiskFreeInterestRateMember\n\n2026-01-15\n\n0001610820\n\nBCTX:SharePurchaseWarrantsMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:CompensationWarrantsMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:SharePurchaseWarrantsMember\n\n2025-07-31\n\n0001610820\n\nBCTX:SharePurchaseWarrantsMember\n\n2026-04-30\n\n0001610820\n\nBCTX:CompensationWarrantsMember\n\n2025-07-31\n\n0001610820\n\nBCTX:CompensationWarrantsMember\n\n2026-04-30\n\n0001610820\n\nBCTX:SharePurchaseWarrantsMember\nBCTX:WarrantOneMember\n\n2026-04-30\n\n0001610820\n\nBCTX:SharePurchaseWarrantsMember\nBCTX:WarrantTwoMember\n\n2026-04-30\n\n0001610820\n\nBCTX:SharePurchaseWarrantsMember\nBCTX:WarrantThreeMember\n\n2026-04-30\n\n0001610820\n\nBCTX:SharePurchaseWarrantsMember\nBCTX:WarrantFourMember\n\n2026-04-30\n\n0001610820\n\nBCTX:SharePurchaseWarrantsMember\nBCTX:WarrantFiveMember\n\n2026-04-30\n\n0001610820\n\nBCTX:SharePurchaseWarrantsMember\nBCTX:WarrantSixMember\n\n2026-04-30\n\n0001610820\n\nBCTX:SharePurchaseWarrantsMember\nBCTX:WarrantSevenMember\n\n2026-04-30\n\n0001610820\n\nBCTX:CompensationWarrantsMember\nBCTX:WarrantOneMember\n\n2026-04-30\n\n0001610820\n\nBCTX:CompensationWarrantsMember\nBCTX:WarrantTwoMember\n\n2026-04-30\n\n0001610820\n\nBCTX:CompensationWarrantsMember\nBCTX:WarrantThreeMember\n\n2026-04-30\n\n0001610820\n\nBCTX:CompensationWarrantsMember\nBCTX:WarrantFourMember\n\n2026-04-30\n\n0001610820\n\nBCTX:CompensationWarrantsMember\nBCTX:WarrantFiveMember\n\n2026-04-30\n\n0001610820\n\nBCTX:CompensationWarrantsMember\nBCTX:WarrantSixMember\n\n2026-04-30\n\n0001610820\n\nBCTX:CompensationWarrantsMember\nBCTX:WarrantSevenMember\n\n2026-04-30\n\n0001610820\n\nBCTX:CompensationWarrantsMember\nBCTX:WarrantEightMember\n\n2026-04-30\n\n0001610820\n\nsrt:MinimumMember\n\n2026-04-30\n\n0001610820\n\nsrt:MaximumMember\n\n2026-04-30\n\n0001610820\n\nsrt:MinimumMember\n\n2025-07-31\n\n0001610820\n\nsrt:MaximumMember\n\n2025-07-31\n\n0001610820\n\nsrt:MinimumMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nsrt:MaximumMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nsrt:MinimumMember\n\n2024-08-01\n2025-07-31\n\n0001610820\n\nsrt:MaximumMember\n\n2024-08-01\n2025-07-31\n\n0001610820\n\nBCTX:BriaProWarrantMember\n\n2023-08-31\n\n0001610820\n\nBCTX:BriaProWarrantMember\n\n2026-04-30\n\n0001610820\n\nBCTX:BriaProWarrantMember\nsrt:MinimumMember\n\n2023-08-31\n\n0001610820\n\nBCTX:BriaProWarrantMember\nsrt:MaximumMember\n\n2023-08-31\n\n0001610820\n\nBCTX:BriaProWarrantMember\nsrt:MinimumMember\n\n2023-08-31\n2023-08-31\n\n0001610820\n\nBCTX:BriaProWarrantMember\nsrt:MaximumMember\n\n2023-08-31\n2023-08-31\n\n0001610820\n\nBCTX:BriaProWarrantMember\nsrt:MinimumMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:BriaProWarrantMember\nsrt:MaximumMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:BriaProWarrantMember\n\n2023-08-31\n2023-08-31\n\n0001610820\n\nBCTX:BriaProWarrantMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:StockOptionPlanMember\nsrt:MaximumMember\n\n2022-08-02\n2022-08-02\n\n0001610820\n\nBCTX:StockOptionPlanMember\n\n2026-04-30\n\n0001610820\n\nBCTX:StockOptionPlanMember\n\n2026-02-01\n2026-02-01\n\n0001610820\n\nBCTX:BriaProOptionsMember\n\n2026-04-30\n\n0001610820\n\nBCTX:BriaProTherapeuticsCorpMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:StockOptionPlanMember\n\n2025-07-31\n\n0001610820\n\nBCTX:StockOptionPlanMember\n\n2024-08-01\n2025-07-31\n\n0001610820\n\nBCTX:StockOptionPlanMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:StockOptionPlanMember\n\n2025-08-01\n2025-08-01\n\n0001610820\n\nBCTX:StockOptionPlanMember\n\n2026-02-01\n\n0001610820\n\nBCTX:ExercisePriceFivePointFiveNineMember\n\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceFivePointFiveNineMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceOneTwoPointFiveZeroMember\n\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceOneTwoPointFiveZeroMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceSixZeroPointZeroZeroMember\n\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceSixZeroPointZeroZeroMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceNineZeroFourPointFiveZeroMember\n\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceNineZeroFourPointFiveZeroMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceOneZeroSevenFourPointZeroZeroMember\n\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceOneZeroSevenFourPointZeroZeroMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceNineZeroSevenPointNineSevenMember\n\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceNineZeroSevenPointNineSevenMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceSevenZeroSixPointFiveZeroMember\n\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceSevenZeroSixPointFiveZeroMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceOneOneTwoSixPointFiveZeroMember\n\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceOneOneTwoSixPointFiveZeroMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceOneTwoSevenZeroPointFiveZeroMember\n\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceOneTwoSevenZeroPointFiveZeroMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceOneZeroSevenFourPointEightThreeMember\n\n2026-04-30\n\n0001610820\n\nBCTX:ExercisePriceOneZeroSevenFourPointEightThreeMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:BriaProOptionsMember\nBCTX:ExercisePriceZeroPointZeroNineThreeThreeMember\n\n2026-04-30\n\n0001610820\n\nBCTX:BriaProOptionsMember\nBCTX:ExercisePriceZeroPointZeroNineThreeThreeMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:BriaProOptionsMember\nBCTX:ExercisePriceZeroPointOneOneZeroEightMember\n\n2026-04-30\n\n0001610820\n\nBCTX:BriaProOptionsMember\nBCTX:ExercisePriceZeroPointOneOneZeroEightMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:BriaProOptionsMember\nBCTX:ExercisePriceZeroPointZeroNineEightFourMember\n\n2026-04-30\n\n0001610820\n\nBCTX:BriaProOptionsMember\nBCTX:ExercisePriceZeroPointZeroNineEightFourMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:BriaProOptionsMember\nBCTX:ExercisePriceZeroPointZeroSevenTwoNineMember\n\n2026-04-30\n\n0001610820\n\nBCTX:BriaProOptionsMember\nBCTX:ExercisePriceZeroPointZeroSevenTwoNineMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:BriaProOptionsMember\nBCTX:ExercisePriceZeroPointOneOneSixTwoMember\n\n2026-04-30\n\n0001610820\n\nBCTX:BriaProOptionsMember\nBCTX:ExercisePriceZeroPointOneOneSixTwoMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:BriaProOptionsMember\nBCTX:ExercisePriceZeroPointOneThreeOneZeroMember\n\n2026-04-30\n\n0001610820\n\nBCTX:BriaProOptionsMember\nBCTX:ExercisePriceZeroPointOneThreeOneZeroMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:BriaProOptionsMember\nBCTX:ExercisePriceZeroPointOneOneSixFiveMember\n\n2026-04-30\n\n0001610820\n\nBCTX:BriaProOptionsMember\nBCTX:ExercisePriceZeroPointOneOneSixFiveMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2025-07-31\n\n0001610820\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:RestrictedStockUnitsRSUMember\nsrt:DirectorMember\n\n2025-09-24\n2025-09-24\n\n0001610820\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2025-09-24\n2025-09-24\n\n0001610820\n\nus-gaap:RestrictedStockUnitsRSUMember\nBCTX:BriaProTherapeuticsCorpMember\n\n2025-07-31\n\n0001610820\n\nus-gaap:RestrictedStockUnitsRSUMember\nBCTX:BriaProTherapeuticsCorpMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nus-gaap:RestrictedStockUnitsRSUMember\nBCTX:BriaProTherapeuticsCorpMember\n\n2026-04-30\n\n0001610820\n\nBCTX:BriaProTherapeuticsCorpMember\nus-gaap:RestrictedStockUnitsRSUMember\nsrt:DirectorMember\n\n2026-04-01\n2026-04-01\n\n0001610820\n\nus-gaap:RestrictedStockUnitsRSUMember\nBCTX:BriaProTherapeuticsCorpMember\n\n2026-04-01\n2026-04-01\n\n0001610820\n\nus-gaap:RestrictedStockUnitsRSUMember\nBCTX:BriaProTherapeuticsCorpMember\n\n2026-04-01\n\n0001610820\n\nus-gaap:PerformanceSharesMember\n\n2025-07-31\n\n0001610820\n\nus-gaap:PerformanceSharesMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nus-gaap:PerformanceSharesMember\n\n2026-04-30\n\n0001610820\n\nus-gaap:PerformanceSharesMember\n\n2025-08-01\n2025-08-01\n\n0001610820\n\nus-gaap:PerformanceSharesMember\n\n2025-08-01\n\n0001610820\n\nsrt:OfficerMember\n\n2025-08-01\n\n0001610820\n\nsrt:ChiefFinancialOfficerMember\n\n2025-08-01\n\n0001610820\n\nsrt:DirectorMember\n\n2025-09-24\n2025-09-24\n\n0001610820\n\nsrt:DirectorMember\n\n2025-09-24\n\n0001610820\n\nus-gaap:PerformanceSharesMember\nsrt:ChiefFinancialOfficerMember\n\n2025-08-01\n2026-04-30\n\n0001610820\n\nBCTX:NationalCancerInstituteMember\n\n2025-08-25\n2025-08-25\n\n0001610820\n\nBCTX:JuneTwoThousandTwentySixOfferingMember\nus-gaap:SubsequentEventMember\n\n2026-06-02\n2026-06-02\n\n0001610820\n\nBCTX:JuneTwoThousandTwentySixOfferingMember\nus-gaap:SubsequentEventMember\n\n2026-06-02\n\n0001610820\n\nBCTX:PlacementAgentWarrantsMember\nus-gaap:SubsequentEventMember\n\n2026-06-02\n\n0001610820\n\nus-gaap:WarrantMember\nus-gaap:SubsequentEventMember\n\n2026-06-02\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nBCTX:Segment\n\niso4217:CAD\n\niso4217:CAD\n\nxbrli:shares\n\nxbrli:pure\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**FORM\n10-Q**\n\n \n\n(Mark\nOne)\n\n☒\n**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe quarterly period ended April 30, 2026**\n\n \n\n☐\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe transition period from                to**               \n\n \n\n**Commission\nFile No. 001-40101**\n\n \n\n**BRIACELL\nTHERAPEUTICS CORP.**\n\n(Exact\nname of registrant as specified in its charter)\n\n \n\n**British\nColumbia, Canada**\n \n**47-1099599**\n\n(State\nor other jurisdiction of\n\nincorporation\nor organization)\n\n \n\n(I.R.S.\nEmployer\n\nIdentification\nNo.)\n\n \n\n**235\n15th Street, Suite 300****,\nWest Vancouver****,\nBC****,\nV7T\n2X1**\n\n(Address\nof Principal Executive Offices, including zip code)\n\n \n\n**604-921-1810**\n\n(Registrant’s\ntelephone number, including area code)\n\n \n\n**N/A**\n\n(Former\nname, former address and former fiscal year, if changed since last report)\n\n \n\nSecurities\nregistered pursuant to Section 12(b) of the Act:\n\n \n\n**Title\nof each class**\n \n**Trading\nSymbol**\n \n**Name\nof each exchange on which registered**\n\nCommon\nshares, no par value\n \nBCTX\n \nThe\nNasdaq Stock Market LLC\n\n \n \n \n \n \n\nWarrants\nto purchase common shares, no par value\n \nBCTXW\n \nThe\nNasdaq Stock Market LLC\n\n \n \n \n \n \n\nWarrants\nto purchase common shares, no par value\n \nBCTXZ\n \nThe\nNasdaq Stock Market LLC\n\n \n \n \n \n \n\nWarrants\nto purchase common shares, no par value\n \nBCTXL\n \nThe\nNasdaq Stock Market LLC\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\nhas been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule\n405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant\nwas required to submit such files). Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting\ncompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”\n“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\n \n☐\nLarge accelerated filer\n☐Accelerated\nfiler\n\n \n☒\nNon-accelerated filer\n☒\nSmaller reporting company\n\n \n \n☒\nEmerging growth company\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐ No ☒\n\n \n\nAs\nof June 9, 2026, 8,699,787 common shares, no par value per share, of the Company were issued and outstanding.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**BRIACELL\nTHERAPEUTICS CORP.**\n\n**Form\n10-Q**\n\n**Table\nof Contents**\n\n \n\n \nPage\n\n[Part I. Financial Information](#a_001)\n3"}